NCT05603013 is a Phase 2 clinical trial of Vinorelbine in Carcinoma, Non-Small-Cell Lung, sponsored by Second Affiliated Hospital of Soochow University.

Who is sponsoring NCT05603013?

NCT05603013 is sponsored by Second Affiliated Hospital of Soochow University.

What drugs are being tested in NCT05603013?

Interventions in NCT05603013: Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, IL-2.

What condition does NCT05603013 study?

NCT05603013 studies Carcinoma, Non-Small-Cell Lung, Carcinoma Breast.

Is NCT05603013 still recruiting?

NCT05603013 is currently status unknown. Last updated 2 November 2022.

Last reviewed 2022-11-02 · How we verify

NCT05603013

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Status unknown Phase 2 Last updated 2 November 2022

What this trial tests

Phase 2 trial testing Vinorelbine in Carcinoma, Non-Small-Cell Lung in 45 participants. Status unknown.

Timeline

30 October 2022

Primary endpoint
1 January 2024

17 October 2024

Quick facts

Lead sponsor	Second Affiliated Hospital of Soochow University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	30 October 2022
Primary completion	1 January 2024
Estimated completion	17 October 2024
Sites	1 location across China

Drugs / interventions tested

Vinorelbine (vinorelbine) — full drug profile →
Radiotherapy
PD-1/PD-L1 inhibitor — full drug profile →
GM-CSF (gm-csf) — full drug profile →
IL-2 — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
Carcinoma Breast — all drugs for Carcinoma Breast →

Sponsor

Second Affiliated Hospital of Soochow University

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung or Carcinoma Breast. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).
Zhao X, Yang M, Zhang J, Kong Y, et al · · 2025 · PMID 41308040 · DOI 10.1177/15330338251400412

Verify or expand the search:

Other trials of Vinorelbine

Trials testing the same drug.

NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07021989 — ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · Phase 2 · not yet recruiting
NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
NCT06908304 — A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC · Phase 3 · recruiting

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Second Affiliated Hospital of Soochow University trials

Trials by the same sponsor.

NCT07327411 — Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors · Phase 2 · not yet recruiting
NCT07241897 — DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes · Phase 3 · not yet recruiting
NCT07267234 — PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) · Phase 2 · not yet recruiting
NCT07095790 — Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke · Phase 4 · recruiting
NCT07002502 — Immune Modulation With PRaG-1 Treatment · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05603013 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Soochow University
Last refreshed: 2 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05603013.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing